Medizin 1

Prof. Dr. med. Markus F. Neurath

Nachwuchsarbeitsgruppe Molekulare der Krebsentstehung und Therapieresistenz bei Leberkrebs und Leber-Metastasierung



Peter Dietrich, Kim Freese, Abdo Mahli, Wolfgang Erwin Thasler, Claus Hellerbrand,Anja Katrin Bosserhoff.Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option. Oncotarget. 2018; 9:3605-3618.

Mahli A, Saugspier M, Koch A, Sommer J, Dietrich P, Lee S, Thasler R, Schulze-Luehrmann J, Luehrmann A, Thasler WE, Müller M, Bosserhoff A, Hellerbrand C. ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis. Gut. 2017

Dietrich P, Koch A, Fritz V, Hartmann A, Bosserhoff AK, Hellerbrand C.Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut. 2017

Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Bosserhoff AK. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition. Oncogene. 2017

Dietrich P, Bosserhoff AK. Melanoma sponge on pigmentation gene to reduce tumour-suppressive microRNAs. Pigment Cell Melanoma Res. 2017


Dietrich P, Bosserhoff AK. DNMT targets MiRacle torching TORCh. Pigment Cell Melanoma Res. 2016;29(4): 399-401


Delic S, Thuy A, Schulze M, Proescholdt MA, Dietrich P, Bosserhoff AK, Riemenschneider MJ. Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority Targets Genes Chromosomes Cancer. 2015;54(7): 433-443

Ruedel A, Dietrich P, Schubert T, Hofmeister S, Hellerbrand C, Bosserhoff AK. Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts. Int J Clin Exp Pathol. 2015;8(5): 4953-62

Hartl J, Dietrich P, Moleda L, Müller-Schilling M, Wiest R. Neuropeptide Y restores non-receptor-mediated vasoconstrictive action in superior mesenteric arteries in portal hypertension. Liver Int. 2015;35(12): 2556-63

Dietrich P, Bosserhoff AK. Modifying microRNAs–another piece of the melanoma puzzle. Pigment Cell Melanoma Res. 2015;28(5): 488-9


Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4): 637-53

Ältere Publikationen

Dietrich P, Moleda L, Kees F, Müller M, Straub RH, Hellerbrand C, Wiest R. Dysbalance in sympathetic neurotransmitter release and action in cirrhotic rats: Impact of exogenous neuropeptide Y. J Hepatol. 2013 Feb;58(2):254-61

Dietrich P, Hellerbrand C. Alkoholische und nichtalkoholische Steatohepatitis – Gemeinsamkeiten und Interaktion von pathophysiologischen Mechanismen. (Review) Verdauungskrankheiten, Jahrgang 30, Nr. 5/2012, S. 233-2

Moleda L, Trebicka J, Dietrich P, Gäbele E, Hellerbrand C, Straub RH, Sauerbruch T, Schoelmerich J, Wiest R. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. Gut 2011; Aug;60(8):1122-32